Biolidics Limited Stock

Equities

8YY

SGXE89830751

Advanced Medical Equipment & Technology

Market Closed - Singapore S.E. 02:39:41 2024-04-29 EDT 5-day change 1st Jan Change
0.011 SGD -8.33% Intraday chart for Biolidics Limited -8.33% -21.43%

Financials

Sales 2022 2.54M 1.87M 2.55M Sales 2023 1.36M 1M 1.37M Capitalization 9.21M 6.77M 9.24M
Net income 2022 -9M -6.62M -9.04M Net income 2023 -2M -1.47M -2.01M EV / Sales 2022 3.87 x
Net cash position 2022 2.02M 1.48M 2.02M Net Debt 2023 1.84M 1.35M 1.85M EV / Sales 2023 8.12 x
P/E ratio 2022
-0.72 x
P/E ratio 2023
-3.33 x
Employees 15
Yield 2022 *
-
Yield 2023
-
Free-Float 54.05%
More Fundamentals * Assessed data
Dynamic Chart
1 day-8.33%
1 week-8.33%
Current month-8.33%
3 months-8.33%
6 months-15.38%
Current year-21.43%
More quotes
1 week
0.01
Extreme 0.01
0.01
1 month
0.01
Extreme 0.01
0.01
Current year
0.01
Extreme 0.01
0.01
1 year
0.01
Extreme 0.01
0.02
3 years
0.01
Extreme 0.01
0.35
5 years
0.01
Extreme 0.01
0.89
10 years
0.01
Extreme 0.01
0.89
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 21-08-31
Corporate Secretary - -
Comptroller/Controller/Auditor 50 22-05-31
Members of the board TitleAgeSince
Chief Executive Officer 59 21-08-31
Director/Board Member 53 23-03-30
Director/Board Member 68 11-26
More insiders
Date Price Change Volume
24-04-29 0.011 -8.33% 1 100
24-04-26 0.012 0.00% 100
24-04-25 0.012 0.00% 59,800

Delayed Quote Singapore S.E., April 29, 2024 at 02:39 am

More quotes
Biolidics Limited is a Singapore-based precision medicine medical technology company. The Company's principal activities are technology development, technology transfer, marketing, selling and distribution of biomedical technology, life and medicine science related products and services; provision of laboratory services; and investment holding. It has three segments: cancer diagnostics, infectious diseases and laboratory services. Cancer diagnostics segment develops and commercializes the ClearCell FX1 System, a fully automated CE-IVD medical device, which separate and enrich cancer cells from blood, allows users of the system to perform liquid biopsies. Infectious diseases segment develops, markets and/or distributes certified test kits with various diagnostic partners. Laboratory services segment offers a range of tests. The laboratory has a regulatory approval from Singapore’s Ministry of Health for molecular microbiology testing and PCR testing services for COVID-19 in Singapore.
More about the company

Annual profits - Rate of surprise